University Hospital Münster

Running trials

• Not yet recruiting

  Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement

  NCT07877298· Source

• Recruiting

  Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD

  NCT07877272· Source

• Not yet recruiting

  Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair

  NCT07380932· Source

• Recruiting

  Registry for Duchenne and Becker Muscular Dystrophy

  NCT07402122· Source

• Recruiting

  Biomechanical Effects of EMST® on Swallowing Function in Parkinson's Disease

  NCT07606547· Source

• Recruiting

  ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

  NCT06801899· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Source

• Recruiting

  A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  NCT07599813· Phase 2· Source

• Recruiting

  Mental Health and Suicidality in Glioblastoma Patients in Germany

  NCT07409584· Source

• Recruiting

  Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices

  NCT07273903· Source

• Recruiting

  Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  NCT07314164· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

  NCT06782490· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

  NCT06821542· Phase 3· Source

• Recruiting

  Video-Tumorboard PLUS

  NCT06980740· Source

• Recruiting

  Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

  NCT06696183· Phase 2· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

  NCT06516965· Phase 3· Source

• Recruiting

  A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

  NCT06780150· Source

• Recruiting

  Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease

  NCT06523608· Source

• Recruiting

  Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

  NCT06122584· Phase 3· Source

• Recruiting

  CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

  2023-503317-29-00· Phase 3· Source

• Recruiting

  Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients

  NCT05944016· Phase 3· Source

• Recruiting

  Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients

  NCT06279793· Phase 2· Source

• Recruiting

  Correlation of Cardiac Output Determined by Echocardiography and Indirect Calorimetry in Critically Ill Patients in Cardiogenic Shock on Extracorporeal Circulatory Life Support

  NCT06369818· Source

• Active, not recruiting

  Systematic Assessment of Treatment Effectiveness for Long-Term Management of Stable Atrial Tachycardia in Inpatient and Outpatient Environments

  NCT07239804· Source

• Recruiting

  Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC

  2023-503558-10-00· Phase 3· Source

• Active, not recruiting

  German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

  NCT06095713· Source

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

  NCT04808505· Phase 3· Source

• Active, not recruiting

  Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

  NCT05501873· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Source

• Recruiting

  Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

  NCT06311708· Source

• Active, not recruiting

  Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

  NCT05555732· Phase 3· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Source

• Active, not recruiting

  RESPONDER-HF Trial

  NCT05425459· Source

• Recruiting

  A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

  NCT05533775· Phase 1/2· Source

• Recruiting

  CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS

  NCT05452213· Phase 4· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Source

• Recruiting

  A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

  NCT05489705· Source

• Recruiting

  A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

  NCT05163288· Phase 3· Source

• Active, not recruiting

  A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

  NCT05281328· Phase 2/3· Source

• Active, not recruiting

  An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

  NCT05300724· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Source

• Recruiting

  Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy (MecMeth/ NOA-24)

  2024-511264-89-00· Phase 2· Source

• Active, not recruiting

  From the Emergency Department Directly to Ablation of Atrial Fibrillation Study

  NCT05294445· Source

Showing 50 of 83.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers6 recruiting
• Atrial fibrillation3 recruiting
• Glioblastoma3 recruiting
• Heart failure3 recruiting
• Parkinson disease3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Amyloidosis2 recruiting
• High blood pressure2 recruiting
• Liver and biliary tract cancer2 recruiting
• Multiple sclerosis2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Depression1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Pompe disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Inferior Vena Cava Pressure as Alternative to Hepatic Venous Pressure for EUS-guided Portal Pressure Gradient Measurement

  NCT07703540· Source

• Completed

  Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)

  NCT06665724· Phase 1· Source

• Completed

  Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease

  NCT06161766· Source

• Terminated

  A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

  NCT06082843· Phase 2· Source

• Completed

  Implementing Spiritual Care in Inpatient Palliative Care

  NCT06206551· Source

• Completed

  A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

  NCT05901649· Source

• Completed

  To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

  NCT05911009· Phase 2· Source

• Completed

  Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).

  NCT06125808· Phase 2· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Source

• Completed

  Electronic Monitoring of Disease Activity in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

  NCT05723848· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Source

• Completed

  A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus

  NCT05306574· Phase 3· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· Source

• Terminated

  A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

  NCT05568225· Phase 2· Source

• Completed

  Effects of Aerobic Exercise During the Early Rehabilitation After Ischemic Stroke

  NCT05690165· Source

• Completed

  Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

  NCT05458856· Phase 3· Source

• Completed

  A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

  NCT05357989· Phase 3· Source

• Terminated

  A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05282121· Phase 2· Source

• Terminated

  A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05161481· Phase 2· Source

• Recruiting

  ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

  NCT04916613· Phase 3· Source

• Terminated

  A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

  NCT04963270· Phase 3· Source

• Recruiting

  RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

  NCT04796350· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Source

• Completed

  Self Tonometry and Transfer of Glaucoma Patients' Data for Improving the Supply Situation

  NCT04698876· Source

• Completed

  Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")

  NCT04474678· Source

• Completed

  Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  NCT04191616· Phase 2· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Source

• Completed

  Physical Training in Glioblastoma Patients During Cytotoxic Therapy

  NCT05015543· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Source

• Completed

  Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

  NCT04227522· Phase 3· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Source

• Terminated

  PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

  NCT04382898· Phase 1/2· Source

• Completed

  A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

  NCT04138277· Phase 3· Source

• Completed

  A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT03900598· Phase 1· Source

• Completed

  Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

  NCT03598270· Phase 3· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· Source

• Completed

  Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

  NCT03250338· Phase 3· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Source

• Completed

  Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

  NCT03399513· Phase 2· Source

• Completed

  A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

  NCT03047395· Phase 3· Source

• Completed

  Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML

  NCT02461537· Phase 3· Source

• Completed

  A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

  NCT02017717· Phase 3· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· Source

• Completed

  Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy

  NCT01827553· Phase 3· Source

Trial sites

• University Hospital Muenster1 trial
• Duplicate_Universitaetsklinikum Muenster /ID# 1484411 trial
• Duplicate_Universitaetsklinikum Muenster /ID# 1504020 trials
• Universitaetsklinikum Muenster /ID# 1538951 trial
• Department of General, Visceral and Transplantation Surgery, University Hospital Münster1 trial
• Department of Neurology, University Hospital Münster1 trial
• Department of Neurosurgery, University Hospital Münster1 trial
• Duplicate_Universitaetsklinikum Muenster /ID# 2396370 trials
• Fabry disease center Münster, Universitätsklinikum Münster1 trial
• Münster Universitätsklinikum1 trial
• Munster University Hospital0 trials
• Universitaetsklinikum Muenster16 trials
• Universitaetsklinikum Muenster - Albert Schweitzer Campus /ID# 1593440 trials
• Universitaetsklinikum Muenster AöR5 trials
• Universitaetsklinikum Muenster /ID# 1530591 trial
• Universitaetsklinikum Muenster /ID# 2020850 trials
• Universitaetsklinikum Muenster /ID# 2020940 trials
• Universitaetsklinikum Muenster /ID# 2259880 trials
• Universitaetsklinikum Muenster /ID# 2399700 trials
• Universitaetsklinikum Muenster /ID# 2439050 trials
• Universitaetsklinikum Muenster /ID# 2456230 trials
• Universitaetsklinikum Muenster /ID# 2494041 trial
• Universitaetsklinikum Muenster /ID# 2567620 trials
• Universitaetsklinikum Muenster /ID# 2567630 trials
• Universitaetsklinikum Muenster /ID# 2624990 trials
• Universitaetsklinikum Muenster /ID# 2630610 trials
• Universitaetsklinikum Muenster /ID# 2696880 trials
• Universitaetsklinikum Muenster /ID# 2718980 trials
• Universitaetsklinikum Muenster /ID# 2801550 trials
• Universitaetsklinikum Muenster - Parent0 trials
• Universitaetsklinikum Muenster (Site 0248)1 trial
• Universitaetsklinikum Muenster (Site 0516)0 trials
• Universitaetsklinikum Muenster (Site 0615)0 trials
• Universitaetsklinikum Muenster (Site 0720)0 trials
• Universitaetsklinikum Muenster (Site 1202)0 trials
• Universitaetsklinikum Muenster, Urologie0 trials
• Universitaetsklinikum Muenster - Von-Esmarch-Strasse /ID# 2551660 trials
• Universitatsklinikum Muenster1 trial
• Universitätsklinikum Münster52 trials
• Universitätsklinikum Münster - Albert Schweitzer Campus5 trials
• Universitätsklinikum Münster - Albert Schweitzer Campus-Pädiatrische Hämatologie und Onkologie (Sit0 trials
• Universitätsklinikum Münster - Albert Schweitzer Campus-Pädiatrische Hämatologie und Onkologie (Site 1141)0 trials
• Universitätsklinikum Münster - Albert Schweitzer Campus (Site 0806)0 trials
• Universitätsklinikum Münster - Albert Schweitzer Campus (Site 1005)0 trials
• Universitätsklinikum Münster - Albert Schweitzer Campus (Site 1405)0 trials
• Universitätsklinikum Münster - Albert Schweitzer Campus (Site 3141)0 trials
• Universitatsklinikum Munster AöR3 trials
• Universitätsklinikum Münster - Children1 trial
• Universitätsklinikum Münster - Gynecology0 trials
• Universitätsklinikum Münster - Klink für Kinderheilkunde und Jugendmedizin / Pädiatrische Hämatologie und Onkologie0 trials
• Universitätsklinikum Münster - Neurologie0 trials
• Universitätsklinikum Münster (UKM)0 trials
• Universitätsklinikum Münster - Zentrale Studienkoordination für innovative Dermatologie (ZID)0 trials
• University hospital Muenster13 trials
• University Hospital Muenster, Department of Nuclear Medicine1 trial
• University Hospital Muenster, Germany0 trials
• University Hospital Muenster, Institute Translational Neurology dept. Neurology0 trials
• University Hospital Munster14 trials
• University Hospital Münster, Department of Neurology2 trials
• University Hospital Munster (UKM)0 trials
• University Hospital of Muenster2 trials
• University Hospital of Münster1 trial
• Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster1 trial
• Universitatsklinikum Munster0 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple sclerosis55 works · 2 trials
• Atopic dermatitis (eczema)34 works · 5 trials
• Sarcoma26 works · 2 trials
• Diffuse large B-cell lymphoma16 works · 1 trial
• Endometriosis14 works · 0 trials
• Endometrial cancer13 works · 0 trials
• Myasthenia gravis13 works · 2 trials
• Hodgkin lymphoma13 works · 1 trial
• Amyloidosis12 works · 3 trials
• Fabry disease6 works · 1 trial
• Primary biliary cholangitis4 works · 0 trials